The 2022 CytoSorb World Users' Meeting focuses
on groundbreaking new applications of the adsorption technology to
celebrate the 10th anniversary of
commercialization
PRINCETON, N.J. and BERLIN, July 1, 2022
/PRNewswire/ -- Under the theme "We Are Changing Medicine: CytoSorb
Therapy - From the Past to the Future," CytoSorbents Corporation
(NASDAQ: CTSO) is bringing together nearly 300 of the world's
leading critical care physicians and renowned scientists, as well
as some of the most experienced cardiovascular and liver
specialists to the 2022 CytoSorb World Users' Meeting (WUM) on
July 2, 2022 in Berlin, Germany. Together, they will discuss
updates on the latest scientific findings, study results, and case
series using CytoSorb blood purification in different clinical
applications.
The kick-off and one of many highlights will be the keynote
speech by Prof. Dr. Bruno Reichart,
the cardiothoracic surgeon who performed the first successful human
heart-lung transplant in Germany
in 1983. He will discuss lessons learned from the renaissance of
xenotransplantation – the transplantation of non-human organs into
human patients – which could someday help to end the global
shortage and waiting lists for donated organs. Solid organ
transplant (e.g. hearts, lungs, kidneys, and livers) is an exciting
new field for CytoSorbents. This includes multiple cardiothoracic
surgery applications of CytoSorb during and after heart-lung
transplants, and includes the burgeoning field of ex vivo
organ perfusion with our E.U. approved
ECOS-300CY®/PerSorb® cartridge, with the goal
of rehabilitating solid organs to improve clinical outcomes.
In recent years, the WUM has established itself as an inclusive
and highly-anticipated interdisciplinary event with pioneers and
power users from all over the world exchanging first-hand insights
into clinical results and experiences with CytoSorb in various
fields of application. A major focus of this year's discussion by
top-level participants will be the combination of CytoSorb and ECMO
to treat lung failure, the use of CytoSorb to reverse septic shock,
and how CytoSorb is helping to advance the treatment of acute liver
failure.
"The dialogue and partnership with CytoSorb users over the past
10 years has proven immensely informative and personally
rewarding," said Christian Steiner,
EVP Marketing & Sales of CytoSorbents and Managing Director of
CytoSorbents Europe. "The combined energy and ideas from this
working group has led to some of the most exciting advances in the
treatment of life-threatening illnesses using our CytoSorb therapy.
Users have embraced the new dimension of blood purification that
CytoSorb has enabled. One powerful example is the treatment of
cytokine storm that is at the core of so many deadly conditions. On
this important anniversary event, we can all be proud that we are
'Working to Save Lives'."
About CytoSorbents Corporation
(NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship product,
CytoSorb®, is approved in the European Union with
distribution in more than 70 countries around the world as an
extracorporeal cytokine adsorber designed to reduce the "cytokine
storm" or "cytokine release syndrome" seen in common critical
illnesses that may result in massive inflammation, organ failure
and patient death. These are conditions where the risk of death can
be extremely high, yet few to no effective treatments exist.
CytoSorb is also being used during and after cardiothoracic surgery
to remove inflammatory mediators that can lead to post-operative
complications, including multiple organ failure. More than 170,000
cumulative CytoSorb devices have been utilized as of March 31, 2022. CytoSorb was originally
introduced into the European Union under CE-Mark as a first-in-kind
cytokine adsorber. Additional CE-Mark label expansions were
received for the removal of bilirubin and myoglobin in clinical
conditions such as liver disease and trauma, respectively, and both
ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb
has also received FDA Emergency Use Authorization in the United States for use in adult critically
ill COVID-19 patients with imminent or confirmed respiratory
failure. The DrugSorb™-ATR Antithrombotic Removal System, which is
based on the same polymer technology as CytoSorb, has also been
granted FDA Breakthrough Designation for the removal of ticagrelor,
as well as FDA Breakthrough Designation for the removal of the
direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban,
in a cardiopulmonary bypass circuit during urgent cardiothoracic
surgery. The Company has initiated two FDA approved pivotal trials
designed to support U.S. marketing approval of DrugSorb-ATR. The
first is the 120-patient, 30 center STAR-T (Safe and
Timely Antithrombotic
Removal-Ticagrelor) randomized, controlled trial
evaluating the ability of intraoperative DrugSorb-ATR use to reduce
perioperative bleeding risk in patients on ticagrelor undergoing
cardiothoracic surgery. The second is the 120-patient, 30 center
STAR‑D (Safe and Timely
Antithrombotic Removal-Direct Oral
Anticoagulants) randomized, controlled trial, evaluating the
intraoperative use of DrugSorb–ATR to reduce perioperative bleeding
risk in patients undergoing cardiothoracic surgery on direct oral
anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous marketed products and products under development based
upon this unique blood purification technology protected by many
issued U.S. and international patents and registered trademarks,
and multiple patent applications pending, including
ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™,
HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more
information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook
and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, future targets and outlooks
for our business, expectations regarding the future impacts of
COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and
are not historical facts and typically are identified by use of
terms such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar words, although some forward-looking
statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent
management's current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 10, 2022, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please click to follow us on Facebook and Twitter
U.S. Company Contact:
Amy
Vogel
305 College Road East
Princeton, NJ 08540
+1 (732) 329-8885
avogel@cytosorbents.com
European Company Contact:
Josephine Kraus
+49 30 765 84 66 23
josephine.kraus@cytosorbents.com
Public Relations Europe:
Marcus Schult
kommponisten
+49 69 13823 ext. 960
+49 172 4238938
marcus.schult@die-kommponisten.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leading-critical-care-and-cardiac-surgery-specialists-from-40-countries-meet-to-discuss-cytosorb-and-the-new-dimension-in-blood-purification-301579573.html
SOURCE CytoSorbents Corporation